China’s CF PharmTech Raises $90M to Advance Respiratory Drug Development

The China-based pharmaceutical company CF PharmTech has raised $90 million to support its pipeline of respiratory drugs.

The Series E investment round was led by New Alliance Capital. New investors CR-CP Life Science Fund, Finnova Capital, GT Capital, Co-stone Asset Management, Xiangcheng Financial Holdings, and Everest Venture Capital, joined earlier investors, including Oriza Holdings, Longmen Venture Capital, GTJA Investment, and CMB International.